Fig. 7. PDGFRβ inhibition does not positively affect critical femoral defect healing.
a Femoral defects performed on C57BL/6J male mice treated with 10 mg/ml Su16f or vehicle in a period of two days before defect surgery till two days post, by oral gavage. Adsorbable collagen sponge was loaded with 5 μg of BMP2 or PBS on a day of surgery. Femurs were evaluated by μCT 9 WPD (Vehicle + PBS n = 5, Vehicle + BMP2 n = 11, Su16f + PBS n = 4, Su16f + BMP2 n = 8). b Imatinib (50 mg/kg/day, ip) was used to inhibit PDGFRβ from two days before surgery till 2 days post-surgery, femurs were evaluated by μCT 9 WPD (Vehicle + PBS n = 3, Vehicle + BMP2 n = 4, Imatinib + PBS n = 4, Imatinib + BMP2 n = 4). c PDGFRβ deletion did not affect critical size femoral defect healing in αSMACrePDGFRβfl/fl animals (tamoxifen induced deletion at −3/0/3 days post defect, Cre- n = 7, Cre+ n = 8). All the results are expressed as mean ± s.e.m. *p < 0.05, ***p < 0.001. Statistical test: One-way ANOVA with Tukey’s post hoc test.